PDGFRa (T674I)

PDGFRA · Variant type: point · HGVS: p.T6741I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Sunitinib	99.8%	0.2%	91.73
2	Cabozantinib	99.0%	1.0%	92.73
3	Nintedanib	98.7%	1.3%	90.23
4	Tivozanib	98.3%	1.8%	92.42
5	Selpercatinib	97.2%	2.8%	96.72
6	Ponatinib	96.4%	3.6%	78.23
7	Erdafitinib	96.2%	3.8%	95.71
8	Sorafenib	96.0%	4.0%	96.72
9	Regorafenib	95.9%	4.1%	95.99
10	Pazopanib	95.6%	4.4%	97.49
11	Pralsetinib	92.6%	7.4%	93.43
12	Avapritinib	92.0%	8.0%	97.73
13	Gilteritinib	91.8%	8.2%	88.97
14	Lenvatinib	91.7%	8.3%	97.74
15	Axitinib	90.0%	10.0%	93.23
16	Pexidartinib	87.3%	12.7%	99.49
17	Brigatinib	87.2%	12.8%	82.96
18	Quizartinib	85.8%	14.2%	99.50
19	Pacritinib	84.9%	15.1%	88.64
20	Erlotinib	81.8%	18.2%	99.75
21	Crizotinib	79.5%	20.6%	91.39
22	Canertinib	79.0%	21.0%	96.49
23	Fostamatinib	78.5%	21.5%	96.74
24	Deucravacitinib	70.7%	29.3%	98.99
25	Ripretinib	68.0%	32.0%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Sunitinib	99.8%	84.2%	+15.6%
Cabozantinib	99.0%	79.3%	+19.7%
Nintedanib	98.7%	98.3%	+0.4%
Tivozanib	98.3%	96.9%	+1.3%
Selpercatinib	97.2%	—	—
Ponatinib	96.4%	100.0%	-3.6%
Erdafitinib	96.2%	94.5%	+1.7%
Sorafenib	96.0%	95.6%	+0.5%
Regorafenib	95.9%	96.7%	-0.7%
Pazopanib	95.6%	74.5%	+21.1%
Pralsetinib	92.6%	—	—
Avapritinib	92.0%	99.1%	-7.2%
Gilteritinib	91.8%	78.1%	+13.8%
Lenvatinib	91.7%	88.0%	+3.7%
Axitinib	90.0%	96.0%	-6.0%
Pexidartinib	87.3%	—	—
Brigatinib	87.2%	—	—
Quizartinib	85.8%	—	—
Pacritinib	84.9%	—	—
Erlotinib	81.8%	—	—
Crizotinib	79.5%	—	—
Canertinib	79.0%	—	—
Fostamatinib	78.5%	—	—
Deucravacitinib	70.7%	—	—
Ripretinib	68.0%	81.5%	-13.5%

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.0ms